Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.

源自小鼠抗人单克隆抗体mAb HB12b，Inebilizumab已经在携带人类CD19基因（hCD19 Tg）的转基因小鼠中显示出了令人印象深刻的耗尽B细胞的活性[1]。Inebilizumab强效耗尽表达CD19的B细胞，包括初级人类B细胞、源自多种肿瘤类型的B细胞系以及癌变B细胞[1]。Inebilizumab在自体ADCC实验中耗尽人类初级B细胞的活性等同于或优于Rituximab，并且对人类体外分化的初级浆细胞展示出强大的ADCC活性[1]。

在体内，Inebilizumab (MEDI-551)（静脉注射；一次性；0-10 mg/kg）通过小鼠的巨噬细胞从血液和脾脏中清除B细胞，并且在体外诱导对小鼠B细胞的吞噬作用[2]。